A combination of RAF dimer inhibitor lifirafenib with MEK inhibitor mirdametinib showed antitumor activity in pre-treated several solid tumor types harboring BRAF mutations, including one patient with BRAF V600E NSCLC [46]. Here, MAP2K7 is linked to non-small cell lung carcinoma.